Browse MYCN

Summary
SymbolMYCN
Namev-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus.
Domain PF00010 Helix-loop-helix DNA-binding domain
PF01056 Myc amino-terminal region
Function

Positively regulates the transcription of MYCNOS in neuroblastoma cells.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001502 cartilage condensation
GO:0001763 morphogenesis of a branching structure
GO:0002053 positive regulation of mesenchymal cell proliferation
GO:0002065 columnar/cuboidal epithelial cell differentiation
GO:0007423 sensory organ development
GO:0008544 epidermis development
GO:0009913 epidermal cell differentiation
GO:0010001 glial cell differentiation
GO:0010463 mesenchymal cell proliferation
GO:0010464 regulation of mesenchymal cell proliferation
GO:0010721 negative regulation of cell development
GO:0014013 regulation of gliogenesis
GO:0014014 negative regulation of gliogenesis
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0030326 embryonic limb morphogenesis
GO:0030856 regulation of epithelial cell differentiation
GO:0035107 appendage morphogenesis
GO:0035108 limb morphogenesis
GO:0035113 embryonic appendage morphogenesis
GO:0035239 tube morphogenesis
GO:0035315 hair cell differentiation
GO:0042063 gliogenesis
GO:0042490 mechanoreceptor differentiation
GO:0042491 auditory receptor cell differentiation
GO:0042733 embryonic digit morphogenesis
GO:0043583 ear development
GO:0045604 regulation of epidermal cell differentiation
GO:0045607 regulation of auditory receptor cell differentiation
GO:0045631 regulation of mechanoreceptor differentiation
GO:0045682 regulation of epidermis development
GO:0045685 regulation of glial cell differentiation
GO:0045686 negative regulation of glial cell differentiation
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048704 embryonic skeletal system morphogenesis
GO:0048705 skeletal system morphogenesis
GO:0048706 embryonic skeletal system development
GO:0048708 astrocyte differentiation
GO:0048710 regulation of astrocyte differentiation
GO:0048712 negative regulation of astrocyte differentiation
GO:0048736 appendage development
GO:0048754 branching morphogenesis of an epithelial tube
GO:0048839 inner ear development
GO:0050768 negative regulation of neurogenesis
GO:0051216 cartilage development
GO:0051961 negative regulation of nervous system development
GO:0060113 inner ear receptor cell differentiation
GO:0060173 limb development
GO:0060541 respiratory system development
GO:0060562 epithelial tube morphogenesis
GO:0060563 neuroepithelial cell differentiation
GO:0061138 morphogenesis of a branching epithelium
GO:0061448 connective tissue development
GO:0072593 reactive oxygen species metabolic process
GO:0098743 cell aggregation
GO:2000377 regulation of reactive oxygen species metabolic process
GO:2000378 negative regulation of reactive oxygen species metabolic process
GO:2000980 regulation of inner ear receptor cell differentiation
Molecular Function -
Cellular Component GO:0000785 chromatin
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolMYCN
Namev-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MYCN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between MYCN and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
17710228NeuroblastomaInhibit immunity (infiltration)Here, we report that the v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (MYCN), the hallmark of aggressive neuroblastoma, repressed expression of monocyte chemoattractant protein-1/CC chemokine ligand 2 (MCP-1/CCL2), a chemokine required for NKT cell chemoattraction. MYCN knockdown in MYCN-amplified neuroblastoma cell lines restored CCL2 production and NKT cell chemoattraction. MYCN overexpression in neuroblastoma xenografts in NOD/SCID mice severely inhibited their ability to attract human NKT cells, T cells, and monocytes. Patients with MYCN-amplified neuroblastoma metastatic to bone marrow had 4-fold fewer NKT cells in their bone marrow than did their nonamplified counterparts, indicating that the MYCN-mediated immune escape mechanism, which we believe to be novel, is operative in metastatic cancer and should be considered in tumor immunobiology and for the development of new therapeutic strategies.
29632319neuroblastomaInhibit immunityIn this review, we will summarize and discuss the latest progress in the study of TNFR2-targeting pharmacological agents and their therapeutic potential based on upregulation or downregulation of Treg activity.
Summary
SymbolMYCN
Namev-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MYCN in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMYCN
Namev-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MYCN in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0170.974
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.210.803
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1230.864
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.0960.273
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5210.708
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.8410.28
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3210.67
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.8380.438
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2570.822
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1530.794
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4780.537
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2180.512
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MYCN in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMYCN
Namev-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYCN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMYCN
Namev-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYCN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYCN.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMYCN
Namev-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYCN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMYCN
Namev-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MYCN expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMYCN
Namev-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MYCN and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMYCN
Namev-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Aliases bHLHe37; N-myc; MYCNOT; NMYC; MODED; ODED; class E basic helix-loop-helix protein 37; neuroblastoma MYC onco ......
Chromosomal Location2p24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MYCN collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.